Aldeyra Therapeutics, Inc. - Common Stock (NQ:ALDX)

1.170 -0.120 (-9.30%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Aldeyra Therapeutics, Inc. - Common Stock

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

Aldeyra Therapeutics Earnings Preview ↗

March 16, 2022

Aldeyra Therapeutics (NASDAQ:ALDX) is set to give its latest quarterly earnings report on Thursday, 2022-03-17. Here's what investors need to know before the announcement....

Via Benzinga

Aldeyra Therapeutics to Participate in Fireside Chat at the Oppenheimer 32nd Annual Healthcare Conference

March 14, 2022

From Aldeyra Therapeutics

Via Business Wire

Aldeyra Therapeutics to Participate in Fireside Chat at the SVB Leerink 2022 Global Healthcare Conference

February 10, 2022

From Aldeyra Therapeutics

Via Business Wire

Aldeyra Therapeutics Announces Publication Of Phase 2 Clinical Trial Of Reproxalap In Allergen Chamber Model ↗

February 01, 2022

Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company discovering and developing innovative therapies for the treatment of immune-mediated diseases, today...

Via Benzinga

The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings ↗

March 13, 2022

Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments...

Via Benzinga

Aldeyra Therapeutics Announces Publication of Phase 2 Clinical Trial of Reproxalap in Allergen Chamber Model

February 01, 2022

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra Therapeutics Announces Positive Top-Line Data from Phase 2 Dry Eye Chamber Clinical Trial of Reproxalap, an Investigational New Drug, Compared to Xiidra®

January 11, 2022

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra Therapeutics to Participate in Fireside Chat at the H.C. Wainwright BioConnect Virtual Conference

January 06, 2022

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra Therapeutics Completes Enrollment in Part 1 of the Phase 3 GUARD Trial of ADX-2191 in Proliferative Vitreoretinopathy

January 04, 2022

From Aldeyra Therapeutics, Inc.

Via Business Wire

55 Biggest Movers From Yesterday ↗

December 22, 2021

Gainers Reliance Global Group, Inc. (NASDAQ: RELI) shares jumped 78.7% to close at $5.45 on Tuesday after gaining around 6% on Monday. Biofrontera Inc. (NASDAQ: BFRI) gained 44.8...

Via Benzinga

Mid-Afternoon Market Update: Dow Jumps Over 500 Points; Rite Aid Shares Spike Higher ↗

December 21, 2021

Toward the end of trading Tuesday, the Dow traded up 1.52% to 35,463.11 while the NASDAQ rose 2.10% to 15,295.45. The S&P also rose, gaining 1.55% to 4,638.74. The U.S. has...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

December 21, 2021

Gainers Jaguar Health (NASDAQ:JAGX) shares increased by 58.26% to $1.82 during Tuesday's regular session. Trading volume for this security as of 12:30 EST is 28.4...

Via Benzinga

Mid-Day Market Update: Crude Oil Rises 3%; Aldeyra Therapeutics Shares Slide ↗

December 21, 2021

Midway through trading Tuesday, the Dow traded up 1.15% to 35,332.22 while the NASDAQ rose 0.94% to 15,122.12. The S&P also rose, gaining 0.80% to 4,605.08. The U.S. has the...

Via Benzinga

38 Stocks Moving In Tuesday's Mid-Day Session ↗

December 21, 2021

Gainers Reliance Global Group, Inc. (NASDAQ: RELI) surged 126% to $6.91 after gaining around 6% on Monday. Biofrontera Inc. (NASDAQ: BFRI) climbed 71.4% to $13.06 after gaining...

Via Benzinga

Stocks Set to Snap Selloff, Dow Eyes Triple-Digit Pop ↗

December 21, 2021

The major benchmarks look set to snap their three-day losing streak today, as investors reassess their anxieties over the fast-spreading omicron variant.

Via Talk Markets

The Daily Biotech Pulse: Aldeyra Sinks On Dry Eye Disease Readout, Sanofi Goes Shopping, Regulatory Setback For Aquestive, Aridis Touts Pan-Coronavirus Antibody Cocktail ↗

December 21, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus CytomX Mid-Phase Study Of ADC In Lung And Head & Neck Cancer Patients...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

December 21, 2021

Gainers Aridis Pharmaceuticals (NASDAQ:ARDS) stock moved upwards by 75.98% to $4.47 during Tuesday's pre-market session. The company's market cap stands at $62.8...

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗

December 21, 2021

Good morning, trader! We're kicking off the day with a dive into some of the biggest pre-market stock movers for Tuesday!

Via InvestorPlace

10 Biggest Price Target Changes For Tuesday ↗

December 21, 2021

B of A Securities lifted the price target on Micron Technology, Inc. (NASDAQ:

Via Benzinga

26 Stocks Moving in Tuesday's Pre-Market Session ↗

December 21, 2021

Gainers Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS) rose 102% to $5.13 in pre-market trading after the company reported pan-coronavirus monoclonal antibody cocktail that retains...

Via Benzinga

Aldeyra's Dry Eye Disease Candidate Disappoints In Late-Stage Study ↗

December 21, 2021

Aldeyra Therapeutics Inc (NASDAQ: ALDX) reported topline data from Phase 3 TRANQUILITY Trial of reproxalap ophthalmic solution for dry eye disease. The trial...

Via Benzinga

Aldeyra Therapeutics Announces Top-Line Results from the Phase 3 TRANQUILITY Trial in Dry Eye Disease

December 20, 2021

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra Therapeutics to Participate in Upcoming Conferences

November 09, 2021

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra Therapeutics Announces Completion of Enrollment in Phase 3 TRANQUILITY Trial in Patients with Dry Eye Disease and Reiterates New Drug Application (NDA) Submission Guidance

November 09, 2021

From Aldeyra Therapeutics, Inc.

Via Business Wire

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

November 02, 2021

Gainers Kiniksa Pharmaceuticals (NASDAQ:KNSA) stock increased by 16.73% to $14.86 during Tuesday's regular session. The current volume of 1.0 million shares is 269.7%...

Via Benzinga

Aldeyra's Dry Eye Disease Trial Meets Primary Endpoint, But Did Not Reach Statistical Significance ↗

November 02, 2021

Aldeyra Therapeutics Inc's (NASDAQ: ALDX) reproxalap achieved the primary endpoint of ocular redness in the Phase 2 trial in patients with dry eye disease. But the ...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

November 02, 2021

Gainers Bone Biologics (NASDAQ:BBLG) shares rose 33.57% to $7.32 during Tuesday's pre-market session. The company's market cap stands at $224.5 million. Artelo...

Via Benzinga

Aldeyra Therapeutics Announces Achievement of Primary Endpoint of Ocular Redness in Randomized, Double-Masked, Vehicle-Controlled Phase 2 Clinical Trial in Dry Eye Disease

November 02, 2021

From Aldeyra Therapeutics, Inc.

Via Business Wire

Aldeyra Therapeutics (ALDX) Q3 2021 Earnings Call Transcript ↗

October 29, 2021

ALDX earnings call for the period ending September 30, 2021.

Via The Motley Fool

Topics Earnings

The Daily Biotech Pulse: Merck Reports Beat-And-Raise Quarter, Pfizer-BioNTech Snag Orders For Additional Vaccine Doses, HCW Cleared For Phase 1 Study Of Pancreatic Cancer Drug ↗

October 28, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Corvus' China Partner Approved For Early Stage Study Of CPI-818 In...

Via Benzinga

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.